Trials / Completed
CompletedNCT06545929
Study of Sunobinop on Craving in Alcohol Use Disorder
A Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 2 Study to Evaluate Impact of Sunobinop (V117957) on Alcohol Craving in Subjects Diagnosed With Moderate to Severe Alcohol Use Disorder and Seeking Treatment
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Imbrium Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy of sunobinop compared to placebo on alcohol craving in subjects with moderate to severe alcohol use disorder and these subjects are seeking treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sunobinop | 1 tablet taken orally at bedtime |
| DRUG | Placebo to match sunobinop | 1 tablet taken orally at bedtime |
Timeline
- Start date
- 2025-01-28
- Primary completion
- 2025-07-14
- Completion
- 2025-07-14
- First posted
- 2024-08-09
- Last updated
- 2025-07-23
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06545929. Inclusion in this directory is not an endorsement.